Načítá se...
Sorafenib fails to trigger ferroptosis across a wide range of cancer cell lines
Sorafenib, a protein kinase inhibitor approved for the treatment of hepatocellular carcinoma and advanced renal cell carcinoma, has been repeatedly reported to induce ferroptosis by possibly involving inhibition of the cystine/glutamate antiporter, known as system x(c)(−). Using a combination of wel...
Uloženo v:
| Vydáno v: | Cell Death Dis |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Nature Publishing Group UK
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8277867/ https://ncbi.nlm.nih.gov/pubmed/34257282 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-021-03998-w |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|